Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core Growth Allocation ETF (AOR) vs FMC Corp (FMC) Price & Performance

iShares Core Growth Allocation ETF
FMC Corp

Price performance

Price movement over the last 24 hours

Key statistics

iShares Core Growth Allocation ETF vs FMC Corp — how do they compare? iShares Core Growth Allocation ETF trades at $69.09, while FMC Corp trades at $10.92 (market cap $1.37B). The key difference: FMC Corp pays a 2.93% dividend while iShares Core Growth Allocation ETF pays none, and iShares Core Growth Allocation ETF is trading nearer its 52-week high, FMC Corp nearer its low. Which is the better fit depends on your goals.

AORFMC
52-Week High
$69.85$43.90
52-Week Low
$61.00$10.80
Market Cap
$1.37B
Sector
Basic Materials
Enterprise Value
$5.51B
Dividend Yield
2.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core Growth Allocation ETF

The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.

Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.

FMC Corp

FMC Corporation (FMC) trades at $10.91, showing minimal daily movement with a 0.18% gain. The stock faces significant fundamental challenges, including a net loss of -$2.24 billion in 2025 and negative profit margins, though recent strategic moves like a $400 million investment from Tessenderlo Group and asset sales aim to reduce debt. Technical indicators are bearish, with the stock trading near key support levels. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings but a consensus price target of $17.00 suggesting substantial upside potential from current levels.

The outlook for FMC hinges on successful debt reduction and the commercial success of new products like rimisoxafen. While the current valuation metrics (P/S: 0.4, P/B: 0.75) appear attractive, the deeply negative profitability and high debt load present significant risks. The potential for a operational turnaround exists, but investors should weigh the high risk of continued losses against the possibility of a recovery driven by new technology and improved financial health.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core Growth Allocation ETF

The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.

Read more on AOR

About FMC Corp

FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.

Read more on FMC